Double benefit of long‐acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis

Summary What is known and objective Somatostatin analogs control GH/IGF‐1 excess in acromegaly. Somatostatin receptors also mediate the complex effects of somatostatin on the gastrointestinal tract and may be defensive in inflammatory bowel diseases, such as ulcerative colitis. We present a patient who showed good response to long‐acting octreotide (OCT‐LAR) treatment in terms of both acromegaly and ulcerative colitis (UC). Case summary A 58‐year‐old female patient with diagnosis of acromegaly and ulcerative colitis was started on long‐acting somatostatin treatment as a first‐line treatment for acromegaly as she refused to undergo transsphenoidal surgery. During the follow‐up period, a significant amelioration was also observed in the course of ulcerative colitis, and clinical remission of both diseases was achieved uneventfully. What is new and conclusion Somatostatin appears to be a promising candidate in the treatment of inflammatory bowel diseases.